Shared on 25 Oct 25

Fair value Increased 0.24%

Analysts have marginally raised their price target for Gland Pharma from ₹1,933.64 to ₹1,938.18. The adjustments reflect slight updates in growth and profitability expectations.

Shared on 11 Oct 25

Fair value Increased 3.80%

Expanded Manufacturing Capacity Will Unleash Market Opportunity

Analysts have raised their price target for Gland Pharma from ₹1,862.83 to ₹1,933.64, citing a modest improvement in fair value estimates and expectations for future earnings. What's in the News Gland Pharma received USFDA approval for Vasopressin in 5% Dextrose Injection, both 40 Units and 20 Units per 100 mL RTU Vials.

Shared on 05 Sep 25

Expanded Manufacturing Capacity Will Unleash Market Opportunity

With consensus forecasts for both future P/E (25.87x) and annual revenue growth (14.5%) unchanged, analysts have maintained Gland Pharma’s fair value at ₹1863. What's in the News Gland Pharma received USFDA approval for Vasopressin in 5% Dextrose Injection (40 Units/100 mL); tentative approval granted for 20 Units/100 mL variant, targeting a $45 million US market.

Shared on 01 Aug 25

Fair value Increased 4.98%

Expanded Manufacturing Capacity Will Unleash Market Opportunity

The consensus analyst price target for Gland Pharma has been revised downward, primarily due to a lower forecasted future P/E multiple while revenue growth expectations remain stable, resulting in a new target of ₹1662. What's in the News Brookfield Corporation and EQT AB are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital Partners also exploring a potential deal; the rising share price and macro/geopolitical headwinds could hinder the transaction, which could reach up to INR 257,110 million ($3 billion) if the open offer is fully subscribed.

Shared on 24 Jul 25

Fair value Increased 5.72%

Launch Of 13 New Molecules Will Expand Product Portfolio

The upward revision in Gland Pharma’s consensus price target from ₹1678 to ₹1774 is primarily driven by a marked increase in forecast revenue growth, while profit margins remain stable. What's in the News Brookfield and EQT are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital and Warburg Pincus also showing interest; soaring share prices and valuation remain potential deal blockers.

Shared on 01 May 25

Fair value Increased 1.45%